Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
Altimmune is a clinical-stage immunotherapeutics company focused on the developmen...
Altimmune is a clinical-stage immunotherapeutic...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
Avid Bioservices is a dedicated contract development and manufacturing organizatio...
Avid Bioservices is a dedicated contract develo...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. ...
CytomX Therapeutics develops Probody⢠therape...
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...
UroGen Pharma Ltd. is a clinical-stage biopharm...
Join the National Investor Network and get the latest information with your interests in mind.